Amount of eligible people: CDEC reviewed the uncertainty in the amount of patients with moderately severe to serious hemophilia B in Canada qualified for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some sufferers who will be classified as acquiring mild or moderate disorder might have a critical bleeding